Get the Stockscreener App
10.73
4.07%
0.42
After Hours:
10.73
Design Therapeutics Inc stock is traded at $10.73, with a volume of 317.22K.
It is up +4.07% in the last 24 hours and down -2.19% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
See More
Previous Close:
$10.31
Open:
$10.41
24h Volume:
317.22K
Relative Volume:
0.95
Market Cap:
$661.74M
Revenue:
-
Net Income/Loss:
$-69.79M
P/E Ratio:
-8.8059
EPS:
-1.2185
Net Cash Flow:
$-54.55M
1W Performance:
+4.17%
1M Performance:
-2.19%
6M Performance:
+75.61%
1Y Performance:
+133.77%
1-Day Range:
$10.41
$10.97
1-Week Range:
$9.90
$10.97
52-Week Range:
$2.60
$11.23
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
10.73 | 635.84M | 0 | -69.79M | -54.55M | -1.2185 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Initiated | Jefferies | Buy |
| Jan-07-26 | Initiated | Oppenheimer | Outperform |
| Dec-03-25 | Initiated | Craig Hallum | Buy |
| Dec-03-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-20-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-15-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-15-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral |
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
Fed Meeting: Will Design Therapeutics Inc benefit from current market trendsDip Buying & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Absci Reports Positive ABS-201 Clinical Progress, Strong Financials, and Advances AI-Designed Therapeutics Pipeline in 2025 Results - Minichart
DSGN Technical Analysis & Stock Price Forecast - Intellectia AI
Aug EndMonth: Will Design Therapeutics Inc benefit from green energy policies2026 Buyback Activity & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Dyno Therapeutics Launches Dyno Psi-Phi, an Agentic AI Suite for Protein Binder Design, at NVIDIA GTC 2026 - Business Wire
Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics - The Manila Times
Myotonic Dystrophy Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma - Barchart
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year HighHere's Why - MarketBeat
Design Therapeutics (DSGN) Receives a New Rating from a Top Analyst - The Globe and Mail
Design Therapeutics (NASDAQ:DSGN) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Jefferies Initiates Coverage On Design Therap... - Benzinga
Design Therapeutics (NASDAQ:DSGN) Now Covered by Jefferies Financial Group - MarketBeat
Jefferies Initiates Coverage on Design Therapeutics With Buy Rating, $15 Price Target - marketscreener.com
Jefferies initiates coverage of Design Therapeutics (DSGN) with buy recommendation - MSN
Jefferies initiates Design Therapeutics stock with buy on drug potential - Investing.com
Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program - Yahoo Finance
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% on Analyst Upgrade - Defense World
Design Therapeutics Inc devrait afficher une perte de 33 cents par actionEarnings AVANT-PAPIER - TradingView
[SCHEDULE 13D/A] Design Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Aug Breakouts: Can Design Therapeutics Inc expand its profit margins2026 Spike Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% After Analyst Upgrade - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Design Therapeutics (DSGN) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Piper Sandler reiterates Overweight on Design Therapeutics stock By Investing.com - Investing.com South Africa
RBC Capital raises Design Therapeutics stock price target on programs By Investing.com - Investing.com Australia
Design Therapeutics, Inc. 2025 Annual Report: GeneTAC® Platform, Genomic Medicine Strategy, and Pipeline Overview - Minichart
Royal Bank Of Canada Forecasts Strong Price Appreciation for Design Therapeutics (NASDAQ:DSGN) Stock - MarketBeat
RBC Capital raises Design Therapeutics stock price target on programs - Investing.com
Piper Sandler reiterates Overweight on Design Therapeutics stock - Investing.com
RBC Raises Price Target on Design Therapeutics to $14 From $13, Keeps Outperform, Speculative Risk - marketscreener.com
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates - Bitget
Design Therapeutics (NASDAQ:DSGN) Announces Earnings Results - MarketBeat
Design Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
DSGN: GeneTACⓇ platform advances four programs for genetic diseases, with strong clinical and financial momentum - TradingView
Design Therapeutics Provides Update on Clinical Trials and Financial Position for 2025 - Quiver Quantitative
Design Therapeutics reports lower-than-expected Q4 net loss - TradingView
DSGN: Net loss rose to $69.8M in 2025 as R&D spending increased; $219.8M cash at year-end - TradingView
Design Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
GeneTAC pipeline advances at Design Therapeutics (NASDAQ: DSGN) in FA, FECD, DM1 and HD - Stock Titan
DSGN: Clinical pipeline advanced, net loss $69.8M, cash reserves $219.8M fund operations into 2029 - TradingView
Design Therapeutics (Nasdaq: DSGN) widens 2025 loss but keeps $219.8M cash - Stock Titan
Three genetic disease trials push ahead at Design Therapeutics - Stock Titan
DSGN Earnings History & Surprises | EPS & Revenue Results | DESIGN THERAPEUTICS INC (NASDAQ:DSGN) - ChartMill
Stock Report: Is Design Therapeutics Inc currently under institutional pressureJuly 2025 Selloffs & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Design Therapeutics Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Edgewise Therapeutics, Inc. (EWTX) Stock Price, News, Quote & History - Yahoo Finance
Earnings Risk: Will Design Therapeutics Inc benefit from green energy policies2025 Big Picture & Daily Entry Point Trade Alerts - baoquankhu1.vn
Antiverse Raises $9.3M Series A to Develop Antibodies for Undruggable Disease Targets and Announces Research Agreement with the Cystic Fibrosis Foundation - Business Wire
Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Monday - MarketBeat
DSGNDesign Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):